Back to News
Market Impact: 0.25

UNH Quantitative Stock Analysis

UNHNDAQ
Company FundamentalsAnalyst InsightsInsider TransactionsHealthcare & BiotechCorporate Earnings
UNH Quantitative Stock Analysis

Validea's guru fundamental report indicates that UNITEDHEALTH GROUP INC (UNH) receives a 69% rating based on the Martin Zweig Growth Investor model, which favors growth stocks with accelerating earnings and sales, reasonable valuations, and low debt; UNH passes several key tests including P/E ratio, revenue growth relative to EPS, and sales growth rate, but fails in areas such as earnings persistence and long-term EPS growth.

Analysis

UnitedHealth Group Inc. (UNH) received a 69% rating from Validea's Growth Investor model, based on Martin Zweig's strategy, a score that is below the 80% threshold typically indicating model interest. The analysis highlights a mixed fundamental profile: UNH satisfies criteria related to its P/E ratio, revenue growth in proportion to EPS growth, sales growth rate, and current quarter earnings, which notably exceeded both the prior three quarters and its historical growth rate. Insider transactions also registered as a positive signal. However, the Zweig model identifies significant shortcomings, as UNH fails on key metrics including quarterly earnings compared to one year ago, the earnings growth rate over the past several quarters, overall earnings persistence, and long-term EPS growth. This divergence between positive current operational metrics and concerns about sustained growth trajectory aligns with the provided mildly negative sentiment score of -0.2 for UNH, suggesting that while immediate financial health appears robust in some areas, the model questions the persistence and acceleration of its earnings growth.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mildly negative

Sentiment Score

-0.20

Ticker Sentiment

NDAQ0.00
UNH-0.20

Key Decisions for Investors

  • Investors should acknowledge the mixed assessment from the Martin Zweig Growth Investor model, which shows UnitedHealth Group passing on current performance and valuation metrics but failing on critical earnings persistence and long-term growth characteristics.
  • Detailed scrutiny is advised to understand the underlying reasons for the flagged weaknesses in earnings consistency and the long-term EPS growth outlook, especially since the Zweig model emphasizes persistent, accelerating growth.
  • Given the 69% model score is below the typical 'interest' threshold and highlights a lack of sustained earnings acceleration, growth-oriented investors may consider a cautious stance or seek further evidence of improving growth persistence before increasing exposure.